442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy

by Jennifer Sims, Patrick Brune, René Hoet, Emmanuel Valentin, LE Suong, Sophie Agaugué, Paul Frohna
Published 2020-11-01

316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A

by Aurélien Marabelle, Martin Wermke, Aude de Gassart, Daniel Olive, Patrick Brune, Emmanuel Valentin, Paul Frohna, Christiane Jungels, Norbert Vey, Elena Garralda, Marina Iché
Published 2020-11-01